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Drug-resistant tuberculosis (TB), and especially multidrug-
resistant (MDR) TB (i.e. resistance to isoniazid and rifampicin 
with or without resistance to other drugs) or extensively 
drug-resistant (XDR) TB (i.e. MDR resistance plus resistance 
to the fluoroquinolones and one of the second-line inject-
ables – kanamycin, amikacin or capreomycin),1 has very 
important implications for affected children and the TB control 
programme. These children are difficult to manage because of 
the increased adverse effects of the second-line anti-TB drugs 
and the prolonged duration of treatment. Furthermore, they 
are often diagnosed late because the history of a drug-resistant 
contact was not obtained or responded to. Children mainly 
have paucibacillary disease, which means that diagnosis of 
a child, especially with MDR TB, usually points to recent 
transmission in the community and therefore a failure of the 
TB control programme. 
Infectiousness of drug-resistant 
Mycobacterium tuberculosis strains
It was initially postulated from experimental (animal) studies 
that isoniazid-resistant, and therefore also MDR Mycobacterium 
tuberculosis strains are less infectious and less likely to cause 
disease than drug-susceptible strains. However, even during 
the 1950s new (no previous anti-TB treatment or treatment for 
< 1 month) isoniazid-resistant TB in children soon followed 
the development of isoniazid-resistant TB in adults. The rates 
of isoniazid-resistant TB for children and adults of similar 
backgrounds and from the same area were similar and the 
rapid rise of drug-resistant TB among adults in New York 
city during 1985 - 1995 also occurred in children.2,3 Snider et 
al. 4 found that the infection rate among children was similar 
and even higher in child contacts of isoniazid-resistant index 
cases compared with drug-susceptible index cases. A study 
from the Western Cape (WC) confirmed similar infection rates 
in childhood contacts of adults with drug-susceptible (48% 
infection) and MDR pulmonary TB (64% infection).5
Transmission was initially confirmed by the same drug 
susceptibility test (DST) results found in adult-child contact 
pairs: 14 of 15 isoniazid-resistant strains (93%) obtained from 
adult-child pairs had identical DST and 20 of 29 (69%) adult-
child pairs with any drug resistance had identical susceptibility 
patterns.6 A study from the WC showed that 18 of 22 MDR 
strains (82%) obtained from adult-child pairs had identical 
susceptibility patterns.7 In 5 of 6 cases where M. tuberculosis 
isolates from the child and adult source case were available 
in a prospective study of child contacts of MDR TB cases, 
the restriction fragment length polymorphism analyses were 
identical.8
Drug resistance surveillance in 
children
Children should be a good source for surveillance of true new 
drug-resistant TB and may accurately reflect the transmission 
of these organisms in the community. Two surveys have been 
done in children < 13 years of age at Tygerberg Children’s 
Hospital: the first from August 1994 through April 1998 and 
the second, in which a community component was included, 
from March 2003 through February 2005.9 The results are 
summarised in Table I.
There was a significant increase in human immunodeficiency 
virus (HIV) infection in children with confirmed TB between 
the surveys. There was no difference in drug resistance 
among HIV-infected compared with HIV-uninfected children. 
Children who were previously treated had a significantly 
higher rate of drug resistance, but in the majority this was still 
due to transmission of a drug-resistant strain.9 An interesting 
finding in the second survey was that there was no significant 
difference in drug resistance between the community-based 
compared with the hospital-based groups (18/130 (14.3%) v. 
23/199 (12.3%), respectively).9 This implies that hospital-based 
surveillance of TB drug resistance in children is a reasonably 
reliable reflection of the drug resistance among children in this 
community. 
Diagnosis of drug-resistant TB
Drug-resistant TB is a microbiological diagnosis. There are 
no clinical or radiological features that distinguish drug-
resistant from drug-susceptible cases. In children a diagnosis 
of drug-resistant TB is more difficult, as they usually have 
paucibacillary disease and specimens for culture are more 
difficult to obtain and less often culture-positive. The diagnosis 
is only confirmed if a resistant M. tuberculosis strain is isolated 
from the child; therefore it is important to obtain specimens 
from all possible sources for culture and DSTs if drug-resistant 
TB is suspected. If a child presenting with TB is a known 
contact of an adult with MDR pulmonary TB, the child is a 
probable MDR TB case and should be managed accordingly. 
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Drug-resistant TB should be suspected if a child deteriorates on 
appropriate, adherent anti-TB treatment or if an adult source 
case with unknown susceptibility pattern: (i) is a treatment 
failure (sputum smear-positive after 5 months’ treatment); 
(ii) is a retreatment case; (iii) is a chronic TB case (TB despite 
2 previous treatment courses); or (iv) has poor adherence to 
treatment.
DSTs could routinely be requested for isoniazid, rifampicin 
and ethambutol. DST for second-line drugs is less reliable, but 
should be done for the aminoglycosides and fluoroquinolones 
to identify XDR TB cases in all newly diagnosed MDR TB 
cases.
Treatment and chemoprophylaxis for 
isoniazid-monoresistant TB in children
A 4-drug intensive phase including ethambutol as the fourth 
drug and a longer continuation phase of 7 months should be 
sufficient if isoniazid resistance is recognised from the onset 
of treatment. Once a treatment regimen fails or the isoniazid 
resistance is diagnosed long after the onset of regimen 3 
treatment (3-drug intensive phase), 2 or more drugs should 
be added to the treatment regimen, as further resistance could 
have developed. 
Rifampicin as a single drug for 6 months could be used as 
chemoprophylaxis in child contacts of infectious isoniazid-
resistant pulmonary TB cases.
Treatment of MDR TB in children
The management of MDR TB is difficult and should preferably 
be done by an expert at a specialised unit. No randomised 
controlled studies are available to guide treatment.  
There are, however, a number of important principles that 
should be adhered to in treating MDR TB cases:
1.    Never add a single drug to a failing regimen.
2.    Give directly observed therapy with daily treatment only. 
3.    Use the adult index case’s isolate DST result if no isolate 
from the child is available.
4.    Give 3 or preferably more drugs to which the patient’s or 
adult source case’s isolate is susceptible and/or naïve. 
5.    Counsel parents at every visit for support, about adverse 
events (which are more difficult to assess in children), and 
importance of adherence to treatment.
6.    Follow-up is essential: clinical, radiological and cultures.
7.    Although the optimal duration of treatment is not known, 
a minimum of 18 months after the first negative culture 
is usually recommended. In children with early primary 
disease (lymph node disease only) this could probably be 
less.
The drugs that could be used in the treatment of MDR TB 
are summarised in Table II. Isoniazid at high dose (15 - 20 
mg/kg/day) may still add value to the treatment regimen 
because many new isoniazid-resistant cases have low-level 
isoniazid resistance.10 It should, however, not replace any other 
drug in such a regimen. Some drugs, such as capreomycin, 
para-aminosalicylic acid (PAS), amoxicillin-clavulanic acid and 
clarithromycin are reserve drugs for the management of XDR 
TB cases. 
Although cycloserine (or terizidone) is usually reserved 
for patients resistant to ethambutol, there is evidence for a 
better response to MDR TB treatment if this drug is added 
from the start even in patients whose isolates are reported as 
ethambutol-susceptible. There is discordance between the DST 
for ethambutol and the gene mutation showing resistance. 
Therefore it is best to start cycloserine in any child with 
MDR TB whose (or whose source case’s) isolate is resistant 
to ethambutol, has extensive pulmonary or extrapulmonary 
Table I. Comparison of two drug resistance surveillance studies at Tygerberg Children’s Hospital
Characteristics  1994 - 1998 survey  2003 - 2005 survey  Odds ratio (95% confidence interval)
All culture-positive cases 338 (%)   323 (%)        
Median age (years)  2.6 (0.06 -13.0)  2.5 (0.04 -12.9)       
Boys   193 (57.1)   173 (53.6)   NS     
Previous TB Rx  32 (9.5)   59 (18.3)   0.47 (0.29 - 0.76)    
HIV test done  166 (49.1)   243 (75.2)   0.32 (0.23 - 0.45)    
HIV-infected*  13 (7.8)   64 (26.3)   0.24 (0.12 - 0.46)    
DST available†  306 (90.5)   307 (95.0)   0.50 (0.26 - 0.96)    
Drug-susceptible  285 (93.1)   267 (87.0)   2.03 (1.13 - 3.67)    
Drug-resistant (all)  21 (6.9)   40 (13.0)   0.49 (0.27 - 0.88)    
Isoniazid-resistant and            
rifampicin-susceptible 14 (4.6)   23 (7.5)   NS     
Multidrug-resistant  7 (2.3)   17 (6.5)   0.40 (0.15 - 1.04)
* As percentage of tests done.
† DST results as percentages of DST done.
HIV = human immunodeficiency syndrome; DSTs = drug susceptibility tests.
Table adapted from Schaaf et al.8
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disease or who has central nervous system involvement 
(cycloserine penetrates the blood-brain barrier well).
In children, amikacin is preferred to kanamycin as it is less 
painful to inject intramuscularly and causes fewer adverse 
effects. An aminoglycoside is part of almost all MDR TB 
treatment regimens and according to the 2006 World Health 
Organization (WHO) MDR TB guidelines should continue for a 
minimum of 6 months.1 
Although the fluoroquinolones are not usually recommended 
for use in children, they form an important part of MDR TB 
treatment. In our experience, adverse effects are rare and 
mainly consist of some nausea and rare cases of insomnia or 
arthralgia. Ofloxacin is currently the preferred drug in children, 
but because levofloxacin has more of the active ingredient 
and can be given at a lower dose with less adverse effects, 
this could become the drug of choice if available. In very 
young children, ciprofloxacin can be used as it is available in a 
suspension.
Gastrointestinal adverse effects are common with 
ethionamide. This can usually be overcome by initially splitting 
the dose into 2 - 3 divided doses per day, which should be 
given as a single dose again as soon as the vomiting or severe 
nausea stops.
Chemoprophylaxis for child contacts of 
MDR TB cases
Chemoprophylaxis for contacts of MDR TB cases is 
controversial. No randomised controlled studies are available. 
The WHO 2006 MDR guidelines recommend isoniazid only for 
the possibility that there could be a drug-susceptible contact, 
and further recommend close clinical follow-up only. Several 
failures of isoniazid or isoniazid/rifampicin to prevent MDR 
TB in contacts have been reported, including 5 recent cases.11 
In a prospective study of contacts of MDR TB source cases, 
2/41 children (5%) who received 6-month chemoprophylaxis 
with 2 drugs for which the adult case’s strain was susceptible 
v. 13/64 children (20%) who did not receive appropriate 
chemoprophylaxis developed TB (p = 0.05).12 This implies that 
MDR chemoprophylaxis could be effective in preventing MDR 
TB. We currently manage our young MDR TB contacts with 
high-dose isoniazid plus two drugs to which the source case 
is susceptible, given for 6 months. Close follow-up (2-monthly 
for the first 6 months and then 6-monthly for 12 - 18 months) 
remains important. In case of known XDR TB, this probably 
will not do, and high-dose isoniazid together with close follow-
up is most likely the only current option available.
Conclusion
MDR TB (and probably XDR TB) is as infectious as drug-
susceptible TB. Drug resistance is a laboratory diagnosis and 
isolates of the child or adult source case are important for 
diagnosis and management of the child. Previously treated 
children have a significantly higher rate of MDR TB, but this 
is most likely transmitted disease that was initially missed, 
although older children with cavitary disease may develop 
drug resistance with poor management of their TB. Aggressive 
treatment is necessary for M(X)DR TB, as there is only one 
opportunity to cure their TB. Treatment is difficult and best 
done by experts at specialised units. 
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Table II. Drugs for the treatment of multidrug-resistant 
tuberculosis 
Antituberculosis      Daily dose  Maximum  
drug          (mg/kg)  dose (mg)
Isoniazid*                  15 - 20  400 
Ethambutol                 20 - 25  2 000  
Ethionamide                 15 - 20  750 
Pyrazinamide†                 25 - 35  2 000  
Aminoglycosides   
Kanamycin                 15 - 30  1 000
Amikacin                 15 - 22.5  1 500  
Fluoroquinolones    
Ofloxacin                 15 - 20  800
Levofloxacin                 7.5 - 10   750
Ciprofloxacin                 30 - 40  2 000 
Moxifloxacin                7.5 - 10  400
Capreomycin                 15 - 30   1 000 
Cycloserine/terizidone            15 - 20  1 000 
Para-aminosalicylic  150  12 000
acid (PAS)  (2 - 3 divided
   doses)
*Additional drug – not to replace any drug in treatment regimen. 
†Susceptibility difficult to test – given as additional drug for full duration of 
treatment.
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